AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
15 Oktober 2024 - 2:00PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management, and post-operative pain
management, today announced that it has launched the cryoSPHERE
MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger
ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB).
The new probe reduces freeze times by 50% when compared to
AtriCure’s first generation cryoSPHERE® cryoablation probe, and
over 30% when compared to the cryoSPHERE®+ probe.
“Every second matters in patient care, and the cryoSPHERE MAX
optimizes efficiency for patients and surgeons,” said Michael
Carrel, President and Chief Executive Officer at AtriCure.
“Strengthening our groundbreaking platform of devices for Cryo
Nerve Block therapy underscores AtriCure’s commitment to enhancing
surgeons' procedural experience and pursuing better outcomes for
patients.”
The cryoSPHERE MAX device continues AtriCure’s innovation for
the cryoNB therapy by reducing the recommended ablation time by 50%
per targeted nerve to 60 seconds. This next generation device
features upgrades in insulation, Nitrous Oxide gas utilization,
tactile tissue feedback, and real time temperature monitoring.
cryoSPHERE MAX features a larger 10 mm ball tip that has 60% more
surface area than the current cryoSPHERE devices, providing
improvements in target tissue coverage, greater heat extraction,
and larger ice ball formation. These improvements enable cryoSPHERE
MAX to significantly reduce freeze times, which reduces total
operative time and improves gas utilization.
“I found the cryoSPHERE MAX probe to be easier to use in
locating the rib/nerve and to maintain contact,” said Dr. Joseph
Lamelas, Cardiothoracic Surgery, University of Miami Health System,
Miami, FL. “The time to reach optimal temperature was very fast as
well, as was the rapid disconnect, making the one-minute freeze
very manageable.”
cryoNB therapy is an adjunctive, non-pharmacological procedure
that uses AtriCure’s cryoICE platform technology to freeze targeted
intercostal nerves and temporarily block pain along peripheral
nerve pathways. Physicians are utilizing cryoNB therapy as part of
their multimodal strategy to provide post-operative pain relief for
several months after surgery. According to The Society of Thoracic
Surgeons, one in seven lung surgery patients (14%) becomes a new
persistent opioid user after surgery, demonstrating the extent to
which opioid addiction is a common post-operative
complication.1
Forward-Looking
Statements
This press release contains “forward-looking statements”– that
is, statements related to future events that by their nature
address matters that are uncertain. Actual results could differ
materially. For details on the uncertainties that may cause our
actual results to be materially different than those expressed in
our forward-looking statements, visit
http://www.atricure.com/forward-looking-statements as well as our
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q
which contain risk factors. We assume no obligation to update any
forward-looking statements contained in this release and the
related attachment as a result of new information or future events
or developments, except as may be required by law.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 37
million people worldwide. Electrophysiologists, cardiothoracic and
thoracic surgeons around the globe use AtriCure technologies for
the treatment of Afib, reduction of Afib related complications and
post-operative pain management. AtriCure’s Isolator® Synergy™
Ablation System is the first medical device to receive FDA approval
for the treatment of persistent Afib. AtriCure’s AtriClip® Left
Atrial Appendage Exclusion System products are the most widely sold
LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is
a minimally invasive procedure that provides a lasting solution for
long-standing persistent Afib patients. AtriCure’s cryoICE
cryoSPHERE® probes are cleared for temporary ablation of peripheral
nerves to block pain, providing pain relief in cardiac and thoracic
procedures. For more information, visit AtriCure.com or follow us
on X (formerly Twitter) @AtriCure.
1The Society of Thoracic Surgeons. (2018). 1 in 7 Lung Surgery
Patients at Risk for Opioid Dependence [Press release]. Retrieved
from
http://sts.org/sites/default/files/press-releases/Opioid_Brescia_FINAL%20FMTb.pdf
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241015227939/en/
Angie Wirick Investor Relations Chief Financial Officer (513)
755-5334 awirick@atricure.com
Valerie Storch-Willhaus Media Relations Vice President,
Corporate Marketing & Communications (612) 605-3311
vstorch-willhaus@atricure.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
Von Nov 2023 bis Nov 2024